Primary-care patients with memory concerns can compare FDA-cleared Alzheimer's blood tests with their regular doctor. The AAIC 2026 primary-care findings showed accuracy rose from 65% before testing to 93% after, nearly matching dementia specialists at 94%. These tests detect blood markers tied to Alzheimer's brain changes, not memory alone. They help a primary-care doctor decide whether symptoms likely come from Alzheimer's or another cause.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed for primary-care diagnosis?
- How does the studied test work?
- Which blood tests are FDA-cleared?
- What do positive, negative, and intermediate results mean?
- What should you ask before testing?
What changed for primary-care diagnosis?
In a Swedish real-world study of 1,310 patients and 165 physicians, doctors gave a diagnosis before and after seeing blood-test results. As the Alzheimer's Association reported in its AAIC release on primary-care accuracy, accuracy rose from 65% to 93% after results.
After results, physicians changed the diagnosis in about one-third of patients. They changed planned follow-up care or testing in more than half. The greatest value was in ruling out Alzheimer's, which can spare patients unneeded referrals and worry.
How does the studied test work?
The study used C2N Diagnostics' PrecivityAD2. It combines two plasma measures, percent p-tau217 and the amyloid-beta 42/40 ratio, into one Amyloid Probability Score, called APS2.
P-tau217 is a phosphorylated form of tau protein linked to Alzheimer's tangles. The amyloid ratio reflects plaque-related protein changes in blood. Together, the score reflects amyloid and phosphorylated-tau pathology.
Which blood tests are FDA-cleared?
By November 2026 four FDA-cleared choices existed, according to Being Patient in its guide to blood-based biomarkers. Many other lab-offered tests lack FDA review.
FDA-cleared tests are aids used with history, exam, and cognitive testing. They are not standalone diagnoses or screening for healthy adults. Patients should ask which exact test the clinic uses and whether it is FDA-cleared.
- Fujirebio Lumipulse
- Roche Elecsys pTau181
- C2N PrecivityAD2
- Roche Elecsys pTau217
What do positive, negative, and intermediate results mean?
A positive result means Alzheimer's brain changes are likely present. A negative result means they are likely absent. Both need a doctor's judgment alongside symptoms and thinking tests.
In the 1,142-person validation behind clearance, a positive PrecivityAD2 had 97.6% positive predictive value versus PET or spinal-fluid testing. A negative had 93.1% negative predictive value, as described by Patient Care Online in its FDA clearance report. About 17.3% received an intermediate "likely positive" result with only 77.3% accuracy. That group often needs more testing or specialist input before any treatment decision.
What should you ask before testing?
FDA cleared PrecivityAD2 on Aug. 20, 2026 for adults age 40 and older with signs or symptoms of cognitive impairment. Bring a symptom timeline, medication list, and a family member who sees day-to-day changes.
A separate AAIC 2026 study followed 2,684 adults with normal thinking and found very high p-tau217 predicted future impairment risk. That use is prognostic, not a current Alzheimer's diagnosis. Ask your doctor to explain whether your test is being used to explain symptoms now.
- Do I have symptoms that make me eligible for testing?
- Which blood test do you order, and is it FDA-cleared?
- What will a positive, negative, or intermediate result change for me?
- Will I need brain imaging, spinal-fluid testing, or a specialist referral next?
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Is Established and What Remains Uncertain for Primary Care Patients
- Early Dementia Detection Across Care Settings in the 2026 NIA Report: What Long-Distance Caregivers Can Check in Their Community
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: Why the Findings May Not Change Care Yet for Adult Children
